TD Waterhouse Canada Inc. Has $662,000 Holdings in United Therapeutics Co. (NASDAQ:UTHR)

TD Waterhouse Canada Inc. lifted its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 862.6% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,877 shares of the biotechnology company's stock after acquiring an additional 1,682 shares during the period. TD Waterhouse Canada Inc.'s holdings in United Therapeutics were worth $662,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of UTHR. Wealthfront Advisers LLC increased its holdings in shares of United Therapeutics by 2,090,573.5% during the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock worth $6,462,018,000 after buying an additional 18,313,424 shares in the last quarter. Norges Bank acquired a new position in shares of United Therapeutics during the fourth quarter worth $151,764,000. FMR LLC increased its holdings in shares of United Therapeutics by 36.5% during the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock worth $519,170,000 after buying an additional 393,777 shares in the last quarter. Thrivent Financial for Lutherans increased its holdings in shares of United Therapeutics by 1,325.5% during the fourth quarter. Thrivent Financial for Lutherans now owns 204,299 shares of the biotechnology company's stock worth $72,085,000 after buying an additional 189,967 shares in the last quarter. Finally, AustralianSuper Pty Ltd increased its holdings in shares of United Therapeutics by 577.1% during the fourth quarter. AustralianSuper Pty Ltd now owns 189,780 shares of the biotechnology company's stock worth $66,962,000 after buying an additional 161,751 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Stock Up 1.9 %

UTHR traded up $5.66 during trading on Monday, reaching $297.04. 410,281 shares of the stock traded hands, compared to its average volume of 447,897. The stock's 50-day moving average is $307.00 and its 200 day moving average is $346.00. United Therapeutics Co. has a 12 month low of $233.31 and a 12 month high of $417.82. The stock has a market capitalization of $13.34 billion, a PE ratio of 13.05, a P/E/G ratio of 0.97 and a beta of 0.63.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating the consensus estimate of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. During the same quarter in the prior year, the business earned $4.36 earnings per share. As a group, equities research analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current year.

Insider Activity

In related news, Director Tommy G. Thompson sold 2,500 shares of the company's stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the sale, the director now owns 8,480 shares in the company, valued at $2,703,424. This represents a 22.77 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Michael Benkowitz sold 10,000 shares of the company's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $348.06, for a total transaction of $3,480,600.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares in the company, valued at $896,950.62. This represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 74,500 shares of company stock worth $24,472,050. Company insiders own 11.90% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. HC Wainwright reiterated a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. UBS Group boosted their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. Wells Fargo & Company reissued an "equal weight" rating and issued a $314.00 price objective (down previously from $395.00) on shares of United Therapeutics in a research note on Friday. Bank of America raised shares of United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price objective on the stock in a research note on Monday, April 21st. Finally, JPMorgan Chase & Co. reduced their price objective on shares of United Therapeutics from $357.00 to $355.00 and set an "overweight" rating on the stock in a research note on Monday, April 21st. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $390.17.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.